The company said on October 13, 2026 that it had announced the election of Paul J. Diaz to its Board of Directors, effective November 1, 2026. The company said he will stand for election by shareholders in May 2027.

1. 01

   The company said on October 13, 2026 that it had announced the election of Paul J. Diaz to its Board of Directors, effective November 1, 2026. The company said he will stand for election by shareholders in May 2027.

2. 02

   The company said the Board appointed Diaz to the Audit Committee and the Research Committee. The company said the Board will consist of 14 members once Diaz joins.

3. 03

   Merck said Diaz is a managing partner at Cressey & Company and previously served as president and chief executive officer of Myriad Genetics, Inc. and Kindred Healthcare. He also sits on the board of Centene Corporation.

4. 04

   The company said Diaz will receive compensation under its non-employee director compensation practices, and that he has no other arrangements tied to his election and no related-party relationships or transactions requiring disclosure under Item 404(a). The compensation practices are described in the "Director Compensation" section of the proxy statement on Schedule 14A filed on April 8, 2026.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.